Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Currently Reading
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr Basit Chaudhry on Challenges With Improving Performance Under OCM

Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.


Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.

Transcript

For practices participating in the OCM that have not improved in performance period 3, what are their biggest challenges in trying to do so?

It’s a complicated subject, and there’s different kind of buckets of where is performance lacking. I’d say that overall, there’s been really good progress it seems, in aggregate, around preventing hospitalizations and doing things like that—skilled nursing facility utilization, diminishing that. I think part of the challenge has been the distribution of the cost structure, particularly with respect to pharmaceuticals. I think for many participants, they feel like that’s largely out of their control. They feel that their care is roughly in line with the evidence-based guidelines, particularly NCCN [National Comprehensive Cancer Network] guidelines. So, the price of pharmaceuticals is difficult for them to manage, and they feel like it’s outside the span of their control. So, I think this has been one of the occurring issues.

I think other issues in terms of performance, I think one thing we see is for many practices, it’s been hard for them to actually interpret what’s driving their performance, particularly what cancers are problematic with respect to methodology or where are they going over, understanding what’s driving that, how effective are different interventions they have going on. There’s a constellation of different issues. I think parallel to that, there are different issues related to the model’s methodology itself. Are prices being projected accurately or in line with what’s actually happening? Things like that. There’s a lot of complex financial modeling that’s involved in OCM, and a lot of what’s being done is predicting prices, and that’s a complicated thing to do in a domain such as oncology.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up